骨髓增生异常综合征患者血清miR-125b-5p、miR-17-5p表达变化及其与临床特征和预后的关系  

Expression changes in serum miR-125b-5p and miR-17-5p and their relationships with the clinical features and prognosis in patients with myelodysplastic syndrome

作　　者：姜铭[1] 徐娟[2] 贲海祥 丁林林 尹红[3] JIANG Ming;XU Juan;BEN Haixiang;DING Linlin;YIN Hong(Laboratory Department,Rugao People's Hospital,Rugao 226500,China;不详)

机构地区：[1]如皋市人民医院检验科,江苏如皋226500 [2]如皋市人民医院血液内科 [3]南通大学附属医院血液病研究室

出　　处：《山东医药》2023年第28期23-26,共4页Shandong Medical Journal

基　　金：南通市卫生健康委员会科研课题(QNZ2022065)。

摘　　要：目的探讨骨髓增生异常综合征(MDS)患者血清miR-125b-5p、miR-17-5p表达变化及其与临床特征和预后的关系。方法选择MDS患者76例(MDS组)、健康志愿者32例(对照组),采集所有研究对象空腹外周静脉血,离心留取血清,采用RT-qPCR法检测血清miR-125b-5p、miR-17-5p表达。比较两组血清miR-125b-5p、miR-17-5p表达;分析血清miR-125b-5p、miR-17-5p表达与MDS患者临床特征和预后的关系。结果MDS组血清miR-125b-5p相对表达量低于对照组,血清miR-17-5p相对表达量高于对照组(P均<0.05)。IPSS-R分级高危+极高危MDS患者血清miR-125b-5p表达低于IPSS-R分级低危+中危MDS患者,血清miR-17-5p表达高于IPSS-R分级低危+中危MDS患者(P均<0.05)。以血清miR-125b-5p、miR-17-5p表达的均数为临界值,将MDS患者分为血清miR-125b-5p低表达者与高表达者、血清miR-17-5p低表达者与高表达者。血清miR-125b-5p低表达者3年总体生存率和3年无进展生存率均低于血清miR-125b-5p高表达者,血清miR-17-5p低表达者3年总体生存率和3年无进展生存率均高于血清miR-17-5p高表达者(P均<0.05)。结论MDS患者血清miR-125b-5p表达下调、血清miR-17-5p表达上调,二者表达变化与IPSS-R分级高危、极高危以及预后不良有关。Objective To investigate the expression changes in levels of serum miR-125b-5p and miR-17-5p and their relationships with the clinical features and prognosis in patients with myelodysplastic syndrome(MDS).Methods Seventy-six patients with MDS(MDS group)and 32 healthy volunteers(control group)were selected.Fasting peripheral venous blood of all subjects was collected,serum was collected by centrifugation,and the expression of miR-125b-5p and miR-17-5p in serum was detected by RT-qPCR.The expression levels of miR-125b-5p and miR-17-5p in serum were compared between the two groups.The relationships between serum miR-125b-5p and miR-17-5p expression and clinical characteristics and prognosis of MDS patients was analyzed.Results The relative expression level of serum miR-125b-5p in the MDS group was lower than that in the control group,and the relative expression level of serum miR-17-5p was higher than that in the control group(both P<0.05).The serum miR-125b-5p expression in patients with high-risk+extremely high-risk MDS classified with IPSS-R was lower than that in patients with low-risk+medium-risk MDS classified with IPSSR,and the serum miR-17-5p expression was higher than that in patients with low-risk+medium-risk MDS classified with IPSS-R(both P<0.05).With the mean of serum miR-125b-5p and miR-17-5p as the critical value,MDS patients were divided into those with low and high expression of serum miR-125b-5p,and those with low and high expression of serum miR-17-5p.The 3-year overall survival rate and 3-year progression-free survival rate of those with low expression of serum miR-125b-5p were lower than those with high expression of serum miR-125b-5p,and the 3-year overall survival rate and 3-year progression-free survival rate of those with low expression of serum miR-17-5p were higher than those with high expression of serum miR-17-5p(all P<0.05).Conclusion The expression of serum miR-125b-5p is down-regulated and serum miR-17-5p is up-regulated in MDS patients,and the changes of both expression levels are as

关 键 词：骨髓增生异常综合征 微小RNA-125b-5p 微小RNA-17-5p 临床特征 预后 

分 类 号：R733.3[医药卫生—肿瘤]